COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -190.57% | -65.35% | -391.58% | -391.58% | 159.69% |
| Total Depreciation and Amortization | -70.24% | 4.14% | 0.00% | 0.00% | 4,148.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 333.82% | -1,026.04% | -1,995.24% | -1,995.24% | -112.79% |
| Change in Net Operating Assets | -50.17% | 1,578.05% | -4.00% | -4.00% | 332.29% |
| Cash from Operations | -132.75% | -70.85% | -189.63% | -189.63% | 367.41% |
| Capital Expenditure | 56.36% | -190.74% | -1,719.35% | -1,719.35% | -1,639.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | -- | -- | -- | -40.00% |
| Cash from Investing | 55.80% | 48,025.93% | -1,719.35% | -1,719.35% | -1,843.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 57.59% | -80.00% | -12.50% | -12.50% | -678.79% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17.21% | -80.00% | -14.29% | -14.29% | -1,335.29% |
| Foreign Exchange rate Adjustments | -160.27% | -137.22% | -582.14% | -582.14% | -25.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.21% | 3,309.78% | -254.41% | -254.41% | 360.31% |